CLINICAL STUDY ON FLEROXACIN IN SURGICAL INFECTIONS

We conducted clinical studies on fleroxacin (FLRX), a new pyridone carboxylic acid derivative, for the treatment of periproctal abscess, secondary infections (due to wounds, burns or surgical operations), mastitis or areolitis and others with once daily dose of 200 mg or 300 mg. We obtained the foll...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1991/06/25, Vol.44(6), pp.614-624
Main Authors: YURA, JIRO, SHINAGAWA, NAGAO, ISHIKAWA, SHU, MASHITA, KEIJI, KINOSHITA, HIROAKI, MORIMOTO, KEN, SAKAI, KATSUJI, MIZUNO, AKIRA, ISHIKAWA, MASAKAZU, SUZUKI, TATSUYA, WATANABE, SUSUMU, SHIBATA, YOSHITAKA, INUKAI, AKIO, MATSUGAKI, KEIJI, OGINO, KENJI, TANABE, KATSUHIKO, MATSUMOTO, KAZUAKI, FUJIMOTO, MIKIO, OHNO, KOICHI, UEDA, TAKAMI, MORIMOTO, YUZURU, OHMORI, KUNIO, HIRATA, SANAE, MURAMATSU, HIDEYUKI
Format: Article
Language:Japanese
Subjects:
Abscess - drug therapy
Abscess - microbiology
Administration, Oral
Adolescent
Adult
Aged
Bacteria - drug effects
Bacteria - isolation & purification
Ciprofloxacin - administration & dosage
Ciprofloxacin - adverse effects
Ciprofloxacin - analogs & derivatives
Ciprofloxacin - pharmacology
Drug Resistance, Microbial
Female
Fleroxacin
Humans
Male
Mastitis - drug therapy
Mastitis - microbiology
Middle Aged
Rectal Diseases - drug therapy
Rectal Diseases - microbiology
Surgical Wound Infection - drug therapy
Surgical Wound Infection - microbiology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted clinical studies on fleroxacin (FLRX), a new pyridone carboxylic acid derivative, for the treatment of periproctal abscess, secondary infections (due to wounds, burns or surgical operations), mastitis or areolitis and others with once daily dose of 200 mg or 300 mg. We obtained the following results. Clinical efficacy was evaluated in total 27 cases including periproctal abscess 11, secondary infection 8, mastitis or areolitis 6, phlegmon 1 and infected atheroma 1. Clinical efficacies were rated as excellent in 14, good in 9, fair in 4 cases. The overall efficacy rate was 85.2%. Bacteriological studies identified 14 strains of aerobic Gram-positive organisms, 12 of aerobicGram-negaive organisms and 6 of anaerobic organisms. The overall bacteriological efficacies were: eradicated in 26 strains, unchanged 2 and unidentified 4, hence the eradication rate was 92.9%. As for side effects, anorexia and nausea were observed in one of the 27 cases. In clinical laboratory tests, slight elevations of GPT and BUN were observed in 1 case each. We consider FLRX to be a useful antimicrobial agent at once daily dose for surgical infections.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.44.614